Array records $85.3 million fiscal year loss

BOULDER – Array BioPharma Inc. (Nasdaq: ARRY) on Tuesday reported revenue of $42 million for its fiscal year ending June 30, down from $69.6 million the year prior.

Boulder-based Array, which focuses primarily on developing drugs to treat various cancers, saw a net loss for the year of $85.3 million, or 69 cents per share, compared to a net loss of $61.9 million, or 57 cents per share last year.

The company’s fourth-quarter revenue and earnings took similar hits. Revenue was $6 million, down from $25.4 million for the same period last year. Net loss was $28.2 million, or 22 cents…